|
Ipsen
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005). The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. History In 1929, Dr. Henri Beaufour founded the Beaufour Laboratories in Dreux. The first product marketed was Roma ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Sohonos
Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. It is a highly selective retinoic acid receptor gamma (RARγ) agonist. It is taken by mouth. It was approved for medical use in Canada in June 2022, and in the United States in August 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses Palovarotene is indicated for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. History Palovarotene is a retinoic acid receptor gamma (RARγ) agonist licensed to Clementia Pharmaceuticals from Roche Pharmaceuticals. At Roche, palovarotene was evaluated in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease (COPD). A one-year trial did not demonstrate a significant benefit on lung density in moderate-to-severe emphysema secondary to sev ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Palovarotene
Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. It is a highly selective retinoic acid receptor gamma (RARγ) agonist. It is taken by mouth. It was approved for medical use in Canada in June 2022, and in the United States in August 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses Palovarotene is indicated for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. History Palovarotene is a retinoic acid receptor gamma (RARγ) agonist licensed to Clementia Pharmaceuticals from Roche Pharmaceuticals. At Roche, palovarotene was evaluated in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease (COPD). A one-year trial did not demonstrate a significant benefit on lung density in moderate-to-severe emphysema secondary to se ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Elafibranor
Elafibranor, sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis. Elafibranor is a dual PPARα/δ agonist. Elafibranor and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro. In June 2024, the US Food and Drug Administration (FDA) granted accelerated approval to elafibranor. The FDA considers it to be a first-in-class medication. Medical uses Elafibranor is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid. Adverse effects The most common adverse reactions include weight gain, diarrhea, abdominal pain, nausea, vomiting, arthralgia, constipation, muscle injury, fracture, gastroesophageal reflux disease, dry mouth, weight l ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Marc De Garidel
Marc de Garidel is a French Biotech Entrepreneur. He is the CEO and Interim Board Chair of Abivax, a French clinical-stage, publicly traded biotechnology company (ABVX at Euronext Paris and Nasdaq Global Market), which he joined in May 2023. He is also the non-executive chairman of the pharmaceutical company Ipsen since 2010. Further, he is on the board of Claris Bio, a Harvard Ophthalmology spin-off. Education Marc de Garidel has a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, has a Master’s in International Management (MIM) from Thunderbird Global School Management in Glendale, Arizona, US, and an executive MBA from Harvard Business School in Boston, Boston, Massachusetts, Etats-Unis. 3] Career In 1983, he started his career at Eli Lilly and Company, where he worked in France, the United States and Germany. 3] In 1995, he joined Amgen as vice president of finance and treasury for Europe. 3] In 1998, he became vice president, corporate controller ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cabozantinib
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small-molecule tyrosine-kinase inhibitor (TKI) of c-Met (HGFR) and VEGFR2, and also inhibits AXL, RET, and FLT3. It was discovered and developed by Exelixis Inc. In November 2012, cabozantinib in its capsule formulation was approved by the US Food and Drug Administration (FDA) under the name Cometriq for treating people with medullary thyroid cancer. The capsule form was approved in the European Union for the same purpose in 2014. In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer and the same was approved in the European Union in September of that year. The brands Cometriq and Cabometyx have different formulations and are not interchangeable. Medical uses Cabozantinib is used in two forms ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Botulinum Toxin
Botulinum toxin, or botulinum neurotoxin (commonly called botox), is a neurotoxic protein produced by the bacterium ''Clostridium botulinum'' and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent. The seven main types of botulinum toxin are named types A to G (A, B, C1, C2, D, E, F and G). New types are occasionally found. Types A and B are capable of causing disease in humans, and are also used commercially and medically. Types C–G are less common; types E and F can cause disease in humans, while the other types cause disease in other animals. Botulinum toxins are among the most potent toxins known to science. Intoxication can occur naturally as a result of eithe ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Odevixibat
Odevixibat, sold under the brand name Bylvay among others, is a medication for the treatment of progressive familial intrahepatic cholestasis. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. It is taken by mouth. Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). It was developed by Albireo Pharma. The most common side effects include diarrhea, abdominal pain, hemorrhagic diarrhea, soft feces, and hepatomegaly (enlarged liver). Odevixibat was approved for medical use in the United States and in the European Union in July 2021. The U.S. Food and Drug Administration considers it to be a first-in-class medication. Medical uses In the United States, odevixibat is indicated for the treatment of pruritus in people three months of age and older with progressive familial intrahepatic cholestasis. In the European Union it is indicated in peo ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Triptorelin
Triptorelin, sold under the brand name Decapeptyl among others, is a medication that acts as an agonist analog of gonadotropin-releasing hormone, repressing expression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2) and a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salt (chemistry), salts. Primary indications include endometriosis, for the reduction of uterine fibroids, to treat prostate cancer, and to treat male hypersexuality with severe sexual deviation. The drug has also been used off label to delay puberty in patients with gender dysphoria. It was patented in 1975 and approved for medical use in 1986. It is on the WHO Model List of Essential Medicines, World Health Organization's List of Essential Medicines. Medical uses Triptorelin is used to treat prostate cancer as part of androgen deprivation therapy. Another common use in the United King ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Fibrodysplasia Ossificans Progressiva
Fibrodysplasia ossificans progressiva (; FOP), also called Münchmeyer disease or formerly myositis ossificans progressiva, is an extremely rare connective tissue disease in which fibrous connective tissue such as muscle, tendons, and ligaments turn into bone tissue (ossification). It is the only known medical condition in which tissue of one organ system changes into that of another. It is a severe, disabling disorder with no cure. FOP is caused by a mutation of the gene ACVR1. The mutation affects the body's repair mechanism, causing fibrous tissue including muscle, tendons, and ligaments to become ossified, either spontaneously or when damaged as the result of trauma. In many cases, otherwise minor injuries can cause joints to become permanently fused as new bone forms, replacing the damaged muscle tissue. This new bone formation (known as "heterotopic ossification") eventually forms a secondary skeleton and progressively restricts the patient's ability to move. Bone formed ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Lanreotide
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Lanreotide (as lanreotide acetate) is manufactured by Ipsen. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007. Medical uses Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secret ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pharmaceutical Companies Established In 1929
Medication (also called medicament, medicine, pharmaceutical drug, medicinal product, medicinal drug or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management. Drugs are classified in many ways. One of the key divisions is by level of control, which distinguishes prescription drugs (those that a pharmacist dispenses only on the medical prescription) from over-the-counter drugs (those that consumers can order for themselves). Medicines may be classified by mode of action, route of administration, biological system affected, or therapeutic effects. The World Health Organization keeps a list of essential medicines. Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Mecasermin
Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity). Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency. A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex. The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficie ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
